cancer therapy News

Delegates now have the option to choose from 3 moderated breakout discussion groups at this conference that is set for February 21-23, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Iain Dukes, Vice President, External R&D, Amgen as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

John Herrmann, Senior Director, Global External R&D, Oncology at Eli Lilly to give a Featured Presentation at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

Claude Gimmi at Boehringer to present at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas

Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

CHI’s Oncology Clinical Trials conference will highlight three Xalkori case studies by Pfizers’ Hakan Sakul, Ph.D., Keith Wilner, Ph.D., and Erling Thor Donnelly, Ph.D., R.A.C. This conference is part of the Molecular Medicine Tri-Conference.

Delegates now have the option to choose from 3 moderated breakout discussion groups at this conference that is set for February 21-23, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Iain Dukes, Vice President, External R&D, Amgen as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

John Herrmann, Senior Director, Global External R&D, Oncology at Eli Lilly to give a Featured Presentation at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

Claude Gimmi at Boehringer to present at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas

Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

With the right knowledge and action people are safely and permanently curing cancer. This how-to book has irrefutable proof of real cancer cures, understanding about healing and teaches detailed directions on exactly how you can cure cancer yourself.

CHI’s Oncology Clinical Trials conference will highlight three Xalkori case studies by Pfizers’ Hakan Sakul, Ph.D., Keith Wilner, Ph.D., and Erling Thor Donnelly, Ph.D., R.A.C. This conference is part of the Molecular Medicine Tri-Conference.

C-RAD AB with its three fully owned subsidiaries is all active in the field of radiation therapy. The order includes four Sentinel scanner systems and will be installed at important university hospitals in Korea.

The Biogerontology Research Foundation in collaboration with the Institute for Biology of Aging funds research in hematopoietic stem cell transplantation in telomerase-knockout mice.

The Dean’s Ivy League Stock Picks of the Day

A new book on breast cancer and disease showcases a scientifically proven natural therapy that creates an environment within the body where cancer and disease cannot thrive and thus allows the body to heal itself.

Monoclonal antibodies in cancer therapy – significant commercial opportunities with developing technologies and innovative products – our new report explains prospects

Blood has several components like-red blood cells, white blood cells, platelets and plasma -and the cells of the blood are produced at the bone marrow. When the cells of the blood grow abnormally, it is called blood cancer or leukaemia

Biotechnology companies are focusing on the development of novel biomarkers to overcome the limitations of current diagnostic tests for cancer, reports Genetic Engineering and Biotechnology News (GEN).